0001209191-22-040279.txt : 20220701 0001209191-22-040279.hdr.sgml : 20220701 20220701164508 ACCESSION NUMBER: 0001209191-22-040279 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220701 FILED AS OF DATE: 20220701 DATE AS OF CHANGE: 20220701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aggarwal Gaurav CENTRAL INDEX KEY: 0001551965 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37490 FILM NUMBER: 221062056 MAIL ADDRESS: STREET 1: C/O PANORAMA CAPITAL STREET 2: 2440 SAND HILL ROAD, SUITE 302 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sierra Oncology, Inc. CENTRAL INDEX KEY: 0001290149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: (605) 376-8679 MAIL ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: ProNAi Therapeutics Inc DATE OF NAME CHANGE: 20040513 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-01 1 0001290149 Sierra Oncology, Inc. SRRA 0001551965 Aggarwal Gaurav C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DR., SUITE 110 SAN MATEO CA 94404 1 0 0 0 Common Stock 2022-07-01 4 D 0 2735853 55.00 D 0 I By: Vivo Opportunity Fund Holdings, L.P. Stock Option (right to buy) 13.87 2022-07-01 4 D 0 1500 0.00 D 2029-11-29 Common Stock 1500 0 D Stock Option (right to buy) 13.98 2022-07-01 4 D 0 6874 0.00 D 2030-06-09 Common Stock 6874 0 D Stock Option (right to buy) 18.11 2022-07-01 4 D 0 6000 0.00 D 2031-06-08 Common Stock 6000 0 D Series A Warrant 13.20 2022-07-01 4 D 0 1455384 0.00 D 2019-11-13 2024-11-13 Common Stock 1455384 0 I By: Vivo Opportunity Fund Holdings, L.P. Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc ("GSK"), Orikum Acquisition Inc. ("Merger Sub") and the Issuer (the "Merger Agreement"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the "Merger"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. The option fully vested on November 29, 2020. At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option. The option fully vested on June 9, 2021. The option fully vested on June 8, 2022. Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the "Series A Warrants") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants. /s/ Gaurav Aggarwal; By: Mary Christina Thomson, Attorney-In-Fact 2022-07-01